They also showed that inhibiting GLUT5 reduces tumor growth and metastasis in vivo, supporting the idea that GLUT5 is not only involved in early-stage prostate carcinogenesis but also plays a critical role in the progression and aggressiveness of the disease. This evidence concerns the gene SLC2A5 and male reproductive organ cancer.